文献速递心律失常

功能验证的SCN5A变异可解读致病性并预测Brugada综合征致死事件

Functionally validated SCN5A variants allow interpretation of pathogenicity and prediction of lethal events in Brugada syndrome.
PubMed 文献 · Eur Heart J · 2021-01-01

本研究在415例日本Brugada综合征注册者中,对55个SCN5A突变(含22个VUS)进行体外功能验证,发现功能证实的LOF-SCN5A突变携带者LAE年发生率为7.9%,显著高于in silico预测携带者的5.1%和全体先证者的2.5%,非LOF变异携带者无LAE。多变量分析显示仅LOF-SCN5A突变和心脏骤停史为LAE独立预测因子。

要点

  • 体外功能验证是区分SCN5A VUS致病性的关键步骤。
  • 功能证实的LOF-SCN5A突变携带者LAE风险高(7.9%/年),非LOF变异者无LAE。
  • 仅LOF-SCN5A突变和心脏骤停史为LAE独立预测因子。

核心结论

  • 体外功能验证是分类SCN5A VUS致病性和进行遗传风险分层的核心。
  • 功能证实的LOF-SCN5A突变是Brugada综合征猝死的遗传负担,其他关联基因证据不足。

研究设计与样本

  • 研究纳入日本Brugada综合征注册队列(n=415),对55个SCN5A突变(含22个VUS)进行异源表达系统全细胞膜片钳功能验证。
  • 另用全外显子测序数据在独立SCN5A突变阴性BrS队列(n=288)和对照(n=372)中进行基因关联分析。

主要发现

  • 功能证实的LOF-SCN5A突变携带者(n=45)电生理传导异常更重,LAE年发生率为7.9%。
  • in silico算法预测的SCN5A携带者LAE年发生率为5.1%,全体BrS先证者为2.5%。
  • 非LOF SCN5A变异携带者(n=15)随访期间无LAE发生。
  • 多变量分析显示仅LOF-SCN5A突变和心脏骤停史为LAE独立预测因子。

关键数值与推荐

  • LOF-SCN5A突变携带者LAE年发生率为7.9%。
  • in silico算法预测的SCN5A携带者LAE年发生率为5.1%。
  • 全体BrS先证者LAE年发生率为2.5%。

临床怎么用

  • 对SCN5A VUS携带者应进行体外功能验证以明确致病性。
  • 功能证实的LOF-SCN5A突变携带者需加强LAE风险监测。
  • 非SCN5A BrS关联基因的罕见变异目前不推荐用于风险分层。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: The prognostic value of genetic variants for predicting lethal arrhythmic events (LAEs) in Brugada syndrome (BrS) remains controversial. We investigated whether the functional curation of SCN5A variations improves prognostic predictability. METHODS AND RESULTS: Using a heterologous expression system and whole-cell patch clamping, we functionally characterized 22 variants of unknown significance (VUSs) among 55 SCN5A mutations previously curated using in silico prediction algorithms in the Japanese BrS registry (n = 415). According to the loss-of-function (LOF) properties, SCN5A mutation carriers (n = 60) were divided into two groups: LOF-SCN5A mutations and non-LOF SCN5A variations. Functionally proven LOF-SCN5A mutation carriers (n = 45) showed significantly severer electrocardiographic conduction abnormalities and worse prognosis associated with earlier manifestations of LAEs (7.9%/year) than in silico algorithm-predicted SCN5A carriers (5.1%/year) or all BrS probands (2.5%/year). Notably, non-LOF SCN5A variation carriers (n = 15) exhibited no LAEs during the follow-up period. Multivariate analysis demonstrated that only LOF-SCN5A mutations and a history of aborted cardiac arrest were significant predictors of LAEs. Gene-based association studies using whole-exome sequencing data on another independent SCN5A mutation-negative BrS cohort (n = 288) showed no significant enrichment of rare variants in 16 985 genes including 22 non-SCN5A BrS-associated genes as compared with controls (n = 372). Furthermore, rare variations of non-SCN5A BrS-associated genes did not affect LAE-free survival curves. CONCLUSION: In vitro functional validation is key to classifying the pathogenicity of SCN5A VUSs and for risk stratification of genetic predictors of LAEs. Functionally proven LOF-SCN5A mutations are genetic burdens of sudden death in BrS, but evidence for other BrS-associated genes is elusive.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Ishikawa T, Kimoto H, Mishima H, et al. Functionally validated SCN5A variants allow interpretation of pathogenicity and prediction of lethal events in Brugada syndrome. Eur Heart J. 2021. PMID: 34219138. doi:10.1093/eurheartj/ehab254

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。